Advertisement

Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials

Published:September 22, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.08.014
      The benefit from statin therapy is proportional to the low-density lipoprotein (LDL) cholesterol reduction. However, adverse events appear to be related to dose rather than LDL cholesterol reduction. Although serious side effects are rare, any comparison of statins requires scrutiny of the relation between therapeutic effect and risk of side effects. This report sought to determine whether the additional LDL cholesterol lowering with rosuvastatin over atorvastatin could be obtained without increased risk of short-term adverse events. Twenty-five studies (∼20,000 patients) were identified that provided 28 comparisons of 1:1 dose ratios, 20 comparisons of 1:2 dose ratios, and 6 comparisons of 1:4 dose ratios. Treatment difference in benefit (percentage of LDL cholesterol reduction) and risk (odds ratios for myalgia, increased alanine aminotransferase >3 times the upper limit of normal, creatine kinase >10 times the upper limit of normal, and percentage of change in glomerular filtration rate, as well as deaths, serious adverse events, and withdrawals caused by adverse events) were estimated using meta-analysis and presented in benefit–risk planes. Rosuvastatin was more efficacious than the same dose of atorvastatin (1:1 dose ratio) or a 2 times higher dose (1:2 dose ratio) of atorvastatin. There was no significant difference between rosuvastatin and a 4 times higher dose of atorvastatin (1:4 dose ratio). There were no significant differences between rosuvastatin and atorvastatin at any dose ratio for adverse events. Percentages of change in GFR improved significantly with both treatments. In conclusion, at 1:1 and 1:2 dose ratios, significant additional decreases in LDL cholesterol were obtained using rosuvastatin compared with atorvastatin at a similar risk of the adverse events presented.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brewer Jr, H.B.
        Benefit-risk assessment of rosuvastatin 10 to 40 milligrams.
        Am J Cardiol. 2003; 92: 23K-29K
        • McKenney J.M.
        • Davidson M.H.
        • Jacobson T.A.
        • Guyton J.R.
        Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
        Am J Cardiol. 2006; 97: 89C-94C
        • Lynd L.D.
        • O'Brien B.J.
        Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.
        J Clin Epidemiol. 2004; 57: 795-803
        • Cook D.J.
        • Sackett D.L.
        • Spitzer W.O.
        Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis.
        J Clin Epidemiol. 1995; 48: 167-171
        • Levey A.S.
        • Greene T.
        • Schluchter M.D.
        • Cleary P.A.
        • Teschan P.E.
        • Lorenz R.A.
        • Molitch M.E.
        • Mitch W.E.
        • Siebert C.
        • Hall P.M.
        • et al.
        Glomerular filtration rate measurements in clinical trials.
        J Am Soc Nephrol. 1993; 4: 1159-1171
        • Deedwania P.C.
        • Gupta M.
        • Stein M.
        • Ycas J.
        • Gold A.
        Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
        Am J Cardiol. 2007; 99: 1538-1543
        • Ferdinand K.C.
        • Clark L.T.
        • Watson K.E.
        • Neal R.C.
        • Brown C.D.
        • Kong B.W.
        • Barnes B.O.
        • Cox W.R.
        • Zieve F.J.
        • Isaacsohn J.
        • et al.
        Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
        Am J Cardiol. 2006; 97: 229-235
        • Olsson A.G.
        • Pears J.
        • McKellar J.
        • Mizan J.
        • Raza A.
        Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
        Am J Cardiol. 2001; 88: 504-508
        • Davidson M.
        • Ma P.
        • Stein E.A.
        • Gotto Jr., A.M.
        • Raza A.
        • Chitra R.
        • Hutchinson H.
        Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
        Am J Cardiol. 2002; 89: 268-275
        • Olsson A.G.
        • Istad H.
        • Luurila O.
        • Ose L.
        • Stender S.
        • Tuomilehto J.
        • Wiklund O.
        • Southworth H.
        • Pears J.
        • Wilpshaar J.W.
        Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
        Am Heart J. 2002; 144: 1044-1051
        • Schneck D.W.
        • Knopp R.H.
        • Ballantyne C.M.
        • McPherson R.
        • Chitra R.R.
        • Simonson S.G.
        Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
        Am J Cardiol. 2003; 91: 33-41
        • Jones P.H.
        • Davidson M.H.
        • Stein E.A.
        • Bays H.E.
        • McKenney J.M.
        • Miller E.
        • Cain V.A.
        • Blasetto J.W.
        Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
        Am J Cardiol. 2003; 92: 152-160
        • Clearfield M.B.
        • Amerena J.
        • Bassand J.P.
        • Hernandez Garcia H.R.
        • Miller S.S.
        • Sosef F.F.
        • Palmer M.K.
        • Bryzinski B.S.
        Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia—Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR).
        Trials. 2006; 7: 35-46
        • Lloret R.
        • Ycas J.
        • Stein M.
        • Haffner S.
        Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
        Am J Cardiol. 2006; 98: 768-773
        • Cheung R.C.
        • Morrell J.M.
        • Kallend D.
        • Watkins C.
        • Schuster H.
        Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
        Int J Cardiol. 2005; 100: 309-316
        • Ballantyne C.M.
        • Bertolami M.
        • Hernandez Garcia H.R.
        • Nul D.
        • Stein E.A.
        • Theroux P.
        • Weiss R.
        • Cain V.A.
        • Raichlen J.S.
        Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
        Am Heart J. 2006; 151: 975-983
        • Strandberg T.E.
        • Feely J.
        • Sigurdsson E.L.
        Twelve week, multicentre, randomised, open label comparison of the effects of rosuvastatin 10mg/d and atorvastatin 10mg/d in high risk adults: a DISCOVERY study.
        Clin Ther. 2004; 26: 1821-1833
        • Leiter L.A.
        • Rosenson R.S.
        • Stein E.
        • Reckless J.P.
        • Schulte K.L.
        • Schleman M.
        • Miller P.
        • Palmer M.
        • Sosef F.
        Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS Study.
        Atherosclerosis. 2007; 194: e154-e164
        • Jukema J.W.
        • Liem A.H.
        • Dunselman P.H.
        • van der Sloot J.A.
        • Lok D.J.
        • Zwinderman A.H.
        LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) Study.
        Curr Med Res Opin. 2005; 21: 1865-1874
        • Schwartz G.G.
        • Bolognese M.A.
        • Tremblay B.P.
        • Caplan R.
        • Hutchinson H.
        • Raza A.
        • Cressman M.
        Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
        Am Heart J. 2004; 148: 105-114
        • Betteridge D.J.
        • Gibson J.M.
        Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
        Diabet Med. 2007; 24: 541-549
        • Berne C.
        • Siewert-Delle A.
        Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS Study.
        Cardiovasc Diabetol. 2005; 4: 7-18
        • Wolffenbuttel B.H.
        • Franken A.A.
        • Vincent H.H.
        Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes—CORALL Study.
        J Intern Med. 2005; 257: 531-539
        • Stalenhoef A.F.
        • Ballantyne C.M.
        • Sarti C.
        • Murin J.
        • Tonstad S.
        • Rose H.
        • Wilpshaar W.
        A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS Study.
        Eur Heart J. 2005; 26: 2664-2672
        • Stein E.
        • Strutt K.
        • Southworth H.
        • Diggle P.
        • Miller E.
        • HeFH Study Group
        Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
        Am J Cardiol. 2003; 92: 1287-1293
        • Insull Jr., W.
        • Ghali J.K.
        • Hassman D.R.
        • JW Y.A.
        • Gandhi S.K.
        • Miller E.
        Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
        Mayo Clin Proc. 2007; 82: 543-550
        • Binbrek A.
        • Elis A.
        • Al-Zaibag M.
        • Eha J.
        • Keber I.
        • Cuevas A.
        • Mukherjee S.
        • Miller T.
        • The DISCOVERY Alpha Study Group
        • Group TDAS
        Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study).
        Curr Ther Res. 2006; 67: 21-43
        • Bots A.F.
        • Kastelein J.J.
        Achieving lipid goals in real life: the Dutch DISCOVERY study.
        Int J Clin Pract. 2005; 59: 1387-1394
        • Fonseca F.A.
        • Ruiz A.
        • Cardona-Munoz E.G.
        • Silva J.M.
        • Fuenmayor N.
        • Marotti M.
        The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value—an Evaluation of Rosuvastatin therapY compared with atorvastatin.
        Curr Med Res Opin. 2005; 21: 1307-1315
        • Middleton A.
        • Binbrek A.S.
        • Fonseca F.A.H.
        • Wilpshaar W.
        • Watkins C.
        • Strandberg T.E.
        Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
        Curr Med Res Opin. 2006; 22: 1181-1191
        • Gupta M.
        • Constance C.
        Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy (DISCOVERY Canada).
        Atheroscler Suppl. 2005; 6: 108-109
        • Jayaram S.
        • Jain M.M.
        • Naikawadi A.A.
        • Gawde A.
        • Desai A.
        Comparative evaluation of the efficacy, safety and tolerability of rosuvastatin 10mg with atorvastatin 10mg in adult patients with hypercholeserolaemia: the first Indian study.
        J Indian Med Assoc. 2004; 102: 48-52
        • Douglas K.
        • O'Malley P.G.
        • Jackson J.L.
        Meta-analysis: the effect of statins on albuminuria.
        Ann Intern Med. 2006; 145: 117-124
        • McClure D.L.
        • Valuck R.J.
        • Glanz M.
        • Murphy J.R.
        • Hokanson J.E.
        Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
        J Clin Epidemiol. 2007; 60: 812-818
        • McClure D.L.
        • Valuck R.J.
        • Glanz M.
        • Hokanson J.E.
        Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present.
        Pharmacoepidemiol Drug Saf. 2007; 16: 132-143
        • Silva M.
        • Mathews M.
        • Jarvis C.
        • Nolan N.
        • Belliveau P.
        • Malloy M.
        • Gandhi P.
        Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
        Clin Ther. 2007; 29: 253-260
        • Danchin N.
        • Chadarevian R.
        • Gayet J.L.
        • Licour M.
        • Valensi P.
        [Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/L in high cardiovascular risk patients (ARIANE study)].
        Ann Cardiol Angeiol (Paris). 2007; 56: 82-87
        • Faergeman O.
        • Hill L.
        • Windler E.
        • Wiklund O.
        • Asmar R.
        • Duffield E.
        • Sosef F.
        Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia.
        Cardiology. 2008; 111: 219-228
        • Zhu J.R.
        • Tomlinson B.
        • Ro Y.M.
        • Sim K.H.
        • Lee Y.T.
        • Sriratanasathavorn C.
        A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
        Curr Med Res Opin. 2007; 23: 3055-3068
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • Kirby A.
        • Sourjina T.
        • Peto R.
        • Collins R.
        • Simes R.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Stamler J.
        • Vaccaro O.
        • Neaton J.D.
        • Wentworth D.
        Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
        Diabetes Care. 1993; 16: 434-444